Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Herpes Zoster Vaccination in SLE: A Pilot Study of Immunogenicity

Joel M. Guthridge, Abigail Cogman, Joan T. Merrill, Susan Macwana, Krista M. Bean, Tiny Powe, Virginia Roberts, Judith A. James and Eliza F. Chakravarty
The Journal of Rheumatology November 2013, 40 (11) 1875-1880; DOI: https://doi.org/10.3899/jrheum.130170
Joel M. Guthridge
From Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abigail Cogman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joan T. Merrill
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Macwana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krista M. Bean
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tiny Powe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Virginia Roberts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith A. James
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eliza F. Chakravarty
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: chakravartye@omrf.org
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    A. Number of interferon-γ (IFN-γ) enzyme-linked immunospot (ELISPOT) spot-forming units with varicella zoster virus (VZV) stimulation by timepoint for patients with systemic lupus erythematosus (SLE) and control subjects. Inset panel B displays the number of IFN-γ ELISPOT spot-forming units with phytohemagglutinin stimulation by timepoint for patients with SLE and control subjects. The median number of spots is displayed as a horizontal bar within the box plot with the interquartile range (IQR) ± range graphed. **Statistical significance using a Mann-Whitney U test with α = 0.05.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Median [interquartile range (IQR)] anti-varicella zoster virus (VZV) IgG index value at each timepoint for patients with systemic lupus erythematosus (SLE) and control subjects. *Statistical significance using a Mann-Whitney U test with α = 0.05.

Tables

  • Figures
    • View popup
    Table 1.

    Baseline demographic and clinical characteristics of participants.

    CharacteristicsSLEHealthy
    n1010
    % female100100
    Age, yrs, mean (SD)60.5 (5.4)*55.3 (4.2)
    White, n77
    African American, n33
    History of shingles, n42
    Taking prednisone, n40
      Mean daily dose, mg6.9—
    Taking HCQ, n70
    Taking MTx, n20
    Baseline SLEDAI, median (range)0 (0–2)—
    • ↵* p < 0.05 compared to healthy subjects. HCQ: hydroxychloroquine; MTX: methotrexate; SLE: systemic lupus erythematosus; SLEDAI: SLE Disease Activity Index.

    • View popup
    Table 2.

    Adverse events and SLE disease activity following HZ vaccine.

    SLEHealthy
    HZ, n00
    Serious adverse event, n00
    ISR (any), n33
      Erythema, tenderness, n33
      Vesicular lesions, n00
    2-week SLEDAI, median (range)0 (0–3)—
    6-week SLEDAI, median (range)1 (0–3)—
    12-week SLEDAI, median (range)0 (0–3)—
    SLE flare, n0—
    • ISR: injection site reaction; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; HZ: herpes zoster.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 40, Issue 11
1 Nov 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Herpes Zoster Vaccination in SLE: A Pilot Study of Immunogenicity
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Herpes Zoster Vaccination in SLE: A Pilot Study of Immunogenicity
Joel M. Guthridge, Abigail Cogman, Joan T. Merrill, Susan Macwana, Krista M. Bean, Tiny Powe, Virginia Roberts, Judith A. James, Eliza F. Chakravarty
The Journal of Rheumatology Nov 2013, 40 (11) 1875-1880; DOI: 10.3899/jrheum.130170

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Herpes Zoster Vaccination in SLE: A Pilot Study of Immunogenicity
Joel M. Guthridge, Abigail Cogman, Joan T. Merrill, Susan Macwana, Krista M. Bean, Tiny Powe, Virginia Roberts, Judith A. James, Eliza F. Chakravarty
The Journal of Rheumatology Nov 2013, 40 (11) 1875-1880; DOI: 10.3899/jrheum.130170
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Keywords

SYSTEMIC LUPUS ERYTHEMATOSUS
HERPES ZOSTER
VACCINE
ZOSTAVAX
INFECTION
CLINICAL TRIAL

Related Articles

Cited By...

More in this TOC Section

  • Vasculitis: What Have We Learned in the Last 50 Years?
  • Demographic, Lifestyle, and Serologic Risk Factors for Rheumatoid Arthritis (RA)–associated Bronchiectasis: Role of RA-related Autoantibodies
  • Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis
Show more Articles

Similar Articles

Keywords

  • systemic lupus erythematosus
  • HERPES ZOSTER
  • VACCINE
  • ZOSTAVAX
  • infection
  • clinical trial

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire